A Study in Healthy Adult Volunteers to Assess the Safety and Pharmacokinetics of an Investigational Imaging Product

Inclusion Criteria: * A female subject is eligible to participate if she is not pregnant and at least one of the following conditions applies: * Not a woman of childbearing potential (WOCBP). OR * A WOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for at least 30 days after the final investigational product (IP) administration. * Female subject must agree not to breastfeed starting at screening, throughout the study period and for 30 days after the final IP administration. * Female subject must not donate ova starting at screening, throughout the study period and for 30 days after the final IP administration. * Male subject with female partner(s) of childbearing potential must agree to use contraception during the treatment period and for at least 30 days after the final IP administration. * Male subject must not donate sperm during the treatment period and for at least 30 days after the final IP administration. * Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom with spermicide for the duration of the pregnancy or time the partner is breastfeeding throughout the study period and for 30 days after the final IP administration. * Subject agrees not to participate in another interventional study while participating in the present study. * Subject has a body mass index range of 18.5 to 32.0 kg/m2, inclusive, and weighs \> 50 kg (for males) or \> 40 kg (for females) at screening. Exclusion Criteria: * Subject has signs of urinary tract infection, abnormalities or disease or has had operational interventions on the urinary tract. * Subject has received any IP within 28 days or 5 half-lives (if known), whichever is longer, prior to screening. * Female subject who has been pregnant within 6 months prior to screening or breastfeeding within 3 months prior to screening. * Subject has a known or suspected hypersensitivity to ASP5354 or any components of the formulation used. * Subject has had previous exposure to ASP5354. * Subject has any of the liver function tests (aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\], alkaline phosphatase, gamma glutamyl transferase and total bilirubin \[TBL\]) \> upper limit of normal (ULN) at day -1. * Subject has any clinically significant history of allergic conditions (including drug allergies, asthma, eczema or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies) prior to IP administration. * Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease or malignancy. * Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection) or fungal (noncutaneous) infection within 2 weeks prior to day -1. * Subject has any clinically significant abnormality following the physical examination, electrocardiogram (ECG) and protocol-defined clinical laboratory tests at screening or day 1. * Subject has a mean pulse \< 45 bpm or \> 90 bpm, mean systolic blood pressure \> 140 mmHg or mean diastolic blood pressure \> 90 mmHg at day -1. * Subject has a mean corrected QT interval using Fridericia's formula (QTcF) \> 430 msec (for males) and \> 450 msec (for females) at day 1 (as determined by the ECG machine). If the mean QTcF exceeds the limits above, 1 additional triplicate (3 measurements) ECG can be taken. * Subject has used any prescribed or nonprescribed drugs (including vitamins, oral contraceptives, hormone replacement therapy or natural and herbal remedies \[e.g., St. John's Wort\]) in the 2 weeks prior to IP administration, except for occasional use of acetaminophen (up to 2 g/day) or topical dermatological products, including corticosteroid products. * Subject has smoked or has used tobacco-containing products or nicotine or nicotine containing products in the past 6 months prior to screening or the subject tests positive for cotinine at screening or day -1. * Subject has a history of consuming more than 14 units of alcoholic beverages per week within 6 months prior to screening or has a history of alcoholism or drug/chemical/substance abuse within the past 2 years prior to screening (Note: 1 unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits/hard liquor). * Subject has used any drugs of abuse (including but not limited to amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and opiates) within 3 months prior to day -1 or the subject tests positive for alcohol or drugs of abuse (including but not limited to amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and opiates) at screening or day -1. * Subject has used any inducer of metabolism (e.g., barbiturates and rifampin) in the 3 months prior to day -1. * Subject has had significant blood loss, donated 1 unit (450 mL) or more of blood or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to day -1. * Subject has a positive serology test for hepatitis B surface antigen, hepatitis B core antibody, hepatitis A virus antibodies (immunoglobulin M), hepatitis C virus antibodies or human immunodeficiency virus p24 antigen at screening. * Subject has any of the renal function tests (blood urea nitrogen and creatinine) \> ULN at day -1. In such a case, the assessment may be repeated once.